1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 37 pages

Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the Adamas Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Adamas Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Adamas Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Adamas Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Adamas Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Adamas Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Adamas Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Adamas Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Adamas Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Adamas Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Adamas Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Adamas Pharmaceuticals, Inc. Snapshot 5
Adamas Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Adamas Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Adamas Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Adamas Pharmaceuticals, Inc. - Pipeline Products Glance 11
Adamas Pharmaceuticals, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Adamas Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Adamas Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Adamas Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Adamas Pharmaceuticals, Inc. - Drug Profiles 16
amantadine hydrochloride ER 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
(amantadine hydrochloride + oseltamivir phosphate + ribavirin) 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ADS-4000 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ADS-8800 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ADS-9000 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
ADS-324 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
(memantine hydrochloride ER + donepezil hydrochloride) 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Adamas Pharmaceuticals, Inc. - Pipeline Analysis 25
Adamas Pharmaceuticals, Inc. - Pipeline Products by Target 25
Adamas Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 26
Adamas Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 27
Adamas Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 28
Adamas Pharmaceuticals, Inc. - Recent Pipeline Updates 29
Adamas Pharmaceuticals, Inc. - Dormant Projects 34
Adamas Pharmaceuticals, Inc. - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Adamas Pharmaceuticals, Inc., Key Information 5
Adamas Pharmaceuticals, Inc., Key Facts 5
Adamas Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Adamas Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Adamas Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Adamas Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Adamas Pharmaceuticals, Inc. - Phase III, 2015 11
Adamas Pharmaceuticals, Inc. - Phase II, 2015 12
Adamas Pharmaceuticals, Inc. - Preclinical, 2015 13
Adamas Pharmaceuticals, Inc. - Discovery, 2015 14
Adamas Pharmaceuticals, Inc. - Unknown, 2015 15
Adamas Pharmaceuticals, Inc. - Pipeline by Target, 2015 25
Adamas Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 26
Adamas Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 27
Adamas Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 28
Adamas Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 29
Adamas Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 34

List of Figures
Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
Adamas Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Adamas Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Adamas Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 25
Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 26
Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 27
Adamas Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.